Simeprevir (TMC435) once daily with peginterferon-α-2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO-4 study

Hepatology Research

Volumn 45, Issue 5, 2015, Pages 501-513

  Kumada, Hiromitsu ^a   Hayashi, Norio ^b   Izumi, Namiki ^c   Okanoue, Takeshi ^d   Tsubouchi, Hirohito ^e   Yatsuhashi, Hiroshi ^f   Kato, Mai ^g   Rito, Ki ^g   Komada, Yuji ^g   Seto, Chiharu ^g   Goto, Shoichiro ^g  

^a TORANOMON HOSPITAL   (Japan)

^b KANSAI ROSAI HOSPITAL   (Japan)

^c MUSASHINO RED CROSS HOSPITAL   (Japan)

^d Saiseikai Imperial Gift Foundation Inc Saiseikai Suita Hospital   (Japan)

^e KAGOSHIMA UNIVERSITY HOSPITAL   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^g Janssen Pharmaceutical KK   (Japan)

Author keywords

Chronic hepatitis C; Direct acting antiviral; Protease inhibitor; Simeprevir (TMC435); Sustained virologic response

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; INTERLEUKIN 28B; PEGINTERFERON ALPHA2B; RIBAVIRIN; SIMEPREVIR;

ADULT; AGED; ALLELE; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; BILIRUBIN BLOOD LEVEL; DECREASED APPETITE; DEPRESSION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERYTHEMA; ERYTHEMA MULTIFORME; FEMALE; FOLLOW UP; GENE MUTATION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HYPERBILIRUBINEMIA; INJECTION SITE REACTION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; NEUTROPENIA; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; PERIPHERAL T CELL LYMPHOMA; PHASE 3 CLINICAL TRIAL; PHOTOSENSITIVITY; PRIORITY JOURNAL; SIDE EFFECT; SKIN ALLERGY; SKIN EXFOLIATION; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84928203902     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12375     Document Type: Article

References (32)

1. Chung H, Ueda T, Kudo M. Changing trends in hepatitis C infection over the past 50 years in Japan. Intervirology 2010; 53: 39-43.
2. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29 (Suppl 1): 74-81.
3. Yuen MF, Hou JL, Chutaputti A. Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol 2009; 24: 346-353.
4. Editors of the Drafting Committee for Hepatitis Management Guidelines: The Japan Society of Hepatology. Guidelines for the Management of Hepatitis C Virus Infection: First edition, May 2012, The Japan Society of Hepatology. Hepatol Res 2013; 43: 1-34.
5. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-264.
6. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-1444.
7. Hadziyannis SJ, Sette H, Jr, Morgan TR etal. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355.
8. Fried MW, Shiffman ML, Reddy KR etal. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
9. Manns MP, McHutchison JG, Gordon SC etal. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
10. Bacon BR, Gordon SC, Lawitz E etal. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217.
11. Hayashi N, Okanoue T, Tsubouchi H, Toyota J, Chayama K, Kumada H. Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. J Viral Hepat 2012; 19: e134-142.
12. Jacobson IM, McHutchison JG, Dusheiko G etal. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
13. Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 2012; 56: 78-84.
14. McHutchison JG, Everson GT, Gordon SC etal. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-1838.
15. Poordad F, McCone J, Jr, Bacon BR etal. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
16. Zeuzem S, Andreone P, Pol S etal. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428.
17. Iino S, Okita K, Omata M, Kumada H, Hayashi N, Tanigawa H. Clinical efficacy of PEG-interferon alpha-2b and ribavirin combination therapy for 48 weeks in chronic hepatitis C patients with genotype 1 and high viral load - Retrospective comparison with interferon alpha-2b and ribavirin combination therapy for 24 weeks. Kantansui 2004; 49: 1099-1121.
18. Kuboki M, Iino S, Okuno T etal. Peginterferon alpha-2a (40KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients. J Gastroenterol Hepatol 2007; 22: 645-652.
19. Sherman KE, Flamm SL, Afdhal NH etal. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-1024.
20. Reesink HW, Fanning GC, Farha KA etal. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology 2010; 138: 913-921.
21. Moreno C, Berg T, Tanwandee T etal. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. J Hepatol 2012; 56: 1247-1253.
22. Manns M, Reesink H, Berg T etal. Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial. Antivir Ther 2011; 16: 1021-1033.
23. Fried MW, Buti M, Dore GJ etal. Once-daily simeprevir (TMC435) with peginterferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 2013; 58: 1918-1929.
24. Zeuzem S, Berg T, Gane E etal. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology 2014; 146: 430-441.
25. Hayashi N, Izumi N, Kumada H etal. Once-daily simeprevir with peginterferon and ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1. J Hepatol 2014; [Epub ahead of print].
26. Izumi N, Hayashi N, Kumada H etal. Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1 patients in Japan: the CONCERTO-2 and -3 studies. J Gastroenterol 2014; 49: 941-953.
27. Lenz O, Verbinnen T, T L etal. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother 2010; 54: 1878-1887.
28. Kieffer TL, Kwong AD, Picchio GR. Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). J Antimicrob Chemother 2010; 65: 202-212.
29. Hayashi N, Seto C, Kato M, Komada Y, Goto S. Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. J Gastroenterol 2014; 49 (1): 138-147.
30. Manns M, Marcellin P, Poordad F etal. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014; Jun 3. [Epub ahead of print].
31. Rauch A, Kutalik Z, Descombes P etal. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338-1345.
32. Kong Y, Wang X, Shang Y etal. Efficacy and tolerability of telaprevir for chronic hepatitis virus C genotype 1 infection: a meta-analysis. PLoS ONE 2012; 7: e52158.